ArticleMedicine2025
A novel T-cell proliferation-related model for predicting the prognosis of head and neck squamous cell carcinoma.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T-Cell Biomarkers.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) have a poor prognosis since its high rates of metastasis and recurrence. T-cell proliferation-related genes (TRGs) act a significant role in tumor pathology through regulating the function, proliferation of immune cells. We designed and validated an individualized TRGs signature for predicting prognosis in HNSCC patients with risk estimation model. We screened out differentially expressed TRGs (DETRGs) in cancer tissues as opposed to paracancerous tissue. gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to investigate the functional involvement of TRGs in the TGCA HNSCC cohort. We constructed a TRG signature using 7 biomarkers which screened by univariate and multivariate analysis and reclassified the HNSCC patients into high- and low-risk group according to prognostic information. After Kaplan-Meier analyzing, we found that patients in high risk was extremely lower in survival than patients in low risk. Combining univariate and multivariate regression analysis, we prove that risk scores is an independent prognostic factor. Further, we explored the immune function and tumor mutation burden (TMB) of our prognostic model. Functional enrichment analyses suggested that TRGs mainly included in the biological pathways related to T-cell and other immune cell response. Different tumor microenvironment, immune cells and TMB can be distinguished clearly according to both risk stratification and subtype clustering. In this study, our team successfully identified specific T-cell proliferation-related genetic biomarkers of HNSCC and established a new prognostic model of HNSCC based on TRGs, which has the outstanding performance in predicting the prognosis of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.